PA
HCAT icon

PharVision Advisers’s Health Catalyst HCAT Stock Holding History

PharVision Advisers’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,109
Closed -$185K – 377
2024
Q4 		$185K Buy
+26,109
New +$208K 0.16% 324

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's HCAT Position: Q1 2025 in Review

PharVision Advisers sold out of Health Catalyst (HCAT) in Q1 2025, closing a stake of 26,109 shares — an estimated $185K sold.

PharVision Advisers first reported a position in HCAT in Q4 2024 and held it in 1 quarter. The position peaked at $185K in Q4 2024. 165 funds tracked by Wall St. Rank hold HCAT as of Q1 2025.

  • PharVision Advisers reported no remaining Health Catalyst position as of Q1 2025 after selling out during the quarter.
  • PharVision Advisers sold 26,109 Health Catalyst shares in Q1 2025, an estimated $185K.
  • PharVision Advisers first reported a position in Health Catalyst in Q4 2024 and held it in 1 quarter.
  • PharVision Advisers's Health Catalyst position peaked at $185K in Q4 2024.
  • 165 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.